The association between endogenous opioid function and morphine responsiveness: a moderating role for...

Area of Science:

• Neuroscience
• Pharmacology
• Pain Research

Background:

• Endogenous opioid (EO) system plays a crucial role in pain modulation.
• Previous research suggests low EO function predicts enhanced analgesia from exogenous opioids.
• The moderating role of endocannabinoids on EO-related predictive effects requires further investigation.

Purpose of the Study:

• To replicate findings on low EO function predicting greater morphine analgesia.
• To investigate if circulating endocannabinoids moderate the relationship between EO function and opioid response.
• To examine the impact of endocannabinoids on pain and subjective responses to morphine and naloxone.

Main Methods:

• 46 individuals with chronic low-back pain participated.
• Blood samples were analyzed for endocannabinoid levels (2-arachidonoylglycerol [2-AG] and N-arachidonoylethanolamine [AEA]).
• Participants underwent laboratory sessions receiving saline placebo, naloxone (opioid antagonist), or morphine under controlled dosing.

Main Results:

• Endocannabinoids (2-AG and AEA) significantly moderated the association between EO function and morphine-induced back pain relief.
• Lower EO function predicted greater morphine analgesia only in individuals with lower endocannabinoid levels.
• Endocannabinoids also moderated EO effects on evoked pain intensity, drug liking, and desire to take again.

Conclusions:

• The effects of the endogenous opioid system on responses to opioid medications are most pronounced when endocannabinoid levels are low.
• These findings highlight the interplay between endogenous opioid and endocannabinoid systems in modulating pain and drug response.
• Results may inform personalized pain medicine by identifying mechanism-based predictors for opioid efficacy.